Ikena Oncology and Inmagene Biopharmaceuticals Announce Agreement for Merger and Private Placement
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 23 2024
0mins
Source: Newsfilter
Merger Announcement: Inmagene Biopharmaceuticals and Ikena Oncology have entered into a definitive merger agreement, with plans to develop IMG-007, an anti-OX40 monoclonal antibody for atopic dermatitis, supported by approximately $175 million in financing.
Company Structure Post-Merger: The combined entity will operate as "ImageneBio, Inc." on NASDAQ, with ownership divided among Ikena stockholders (34.8%), Inmagene equity holders (43.5%), and financing investors (21.7%), and is expected to close in mid-2025.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
